5-acetyl-6-ethyl-1,2-dihydro-2-oxonicotinonitrile | 88302-05-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-acetyl-6-ethyl-1,2-dihydro-2-oxonicotinonitrile
• 英文别名: 5-Acetyl-6-ethyl-2-oxo-1,2-dihydropyridine-3-carbonitrile；5-acetyl-6-ethyl-2-oxo-1H-pyridine-3-carbonitrile
• CAS: 88302-05-0
• 化学式: C₁₀H₁₀N₂O₂
• 分子量: 190.202
• InChiKey: YNBPNMUKSRLSBO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  70
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1,2-dihydro-6-methyl-2-oxo-5-(n-propanoyl)-3-pyridinecarbonitrile 、 5-acetyl-6-ethyl-1,2-dihydro-2-oxonicotinonitrile 、 2,4-己二酮 、 N,N-二甲基甲酰胺二甲基缩醛 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以to yield, as a liquid, 3-dimethylaminomethylene-2,4-hexanedione的产率得到3-((dimethylamino)methylene)hexane-2,4-dione
  参考文献：
  名称：

  5-Alkyl-1,6-naphthyridin-2(1H)-ones and cardiotonic use thereof

  摘要：

  1-R"-3-Q-4-R'-5-R-1,6-萘啶并[2(1H)-酮]（I）或其盐，其中R为低碳基，R'为氢或甲基，R"为氢或低碳基，Q为氢、羟基、氨基、氰基、氨基甲酰基、羧基或氨基甲酰基，作为强心剂（I，Q为氢、羟基、氨基、氰基或氨基甲酰基）和/或其中间体（I，Q为羧基、氨基甲酰基、氢、氨基、氰基或氨基甲酰基）有用。还显示了3-Q'-4-R'-5-(RCO)-6-[2-(二低碳基氨基)乙烯基]-2(1H)-吡啶酮（II）或其盐，其中R和R'如上所述，Q'为氢或氰基，它们作为强心剂（II，Q'为氢）和/或中间体（II，Q'为氰基或氢）有用。显示了制备公式I和II化合物的过程。

  公开号：

  US04517190A1

文献信息

• 5-(4-Thiazolyl)-6-alkyl-2(1H)-pyridinones and their cardiotonic use
  申请人：Sterling Drug Inc.

  公开号：US04469699A1

  公开（公告）日：1984-09-04

  3-Q-4-R.sub.2 -5-(2-Q'-5-R.sub.3 -4-thiazolyl)-6-R.sub.1 -2(1H)-pyridinones (I), where R.sub.1 is alkyl having from one to four carbon atoms, R.sub.2 is hydrogen or methyl, R.sub.3 is hydrogen or alkyl having from one to three carbon atoms, Q is amino, carbamyl, carboxy, cyano or hydrogen, and Q' is alkyl having from one to four carbon atoms, amino or R.sub.4 NH where R.sub.4 is alkyl having from one to four carbon atoms, or acid-addition salts thereof where at least one of Q and Q' is amino or Q' is R.sub.4 NH, are useful as cardiotonics (I where Q is amino, cyano or hydrogen) and/or as intermediates (I where Q is cyano, carbamyl or carboxy). Also shown as intermediates are 1,2-dihydro-4-R.sub.2 -5-[R.sub.3 CH(Br)CO]-6-R.sub.1 -2-oxo-3-pyridinecarbonitriles (II), and, also, processes for preparing I and II.

  3-Q-4-R.sub.2 -5-(2-Q'-5-R.sub.3 -4-噻唑基)-6-R.sub.1 -2(1H)-吡啶酮(I)，其中R.sub.1是具有一至四个碳原子的烷基，R.sub.2是氢或甲基，R.sub.3是氢或具有一至三个碳原子的烷基，Q是氨基，氨基甲酰基，羧基，氰基或氢，而Q'是具有一至四个碳原子的烷基，氨基或R.sub.4 NH，其中R.sub.4是具有一至四个碳原子的烷基，或它们的酸加成盐，其中至少有一个Q和Q'为氨基或Q'为R.sub.4 NH，可用作心脏强心剂（其中Q为氨基，氰基或氢）和/或中间体（其中Q为氰基，氨基甲酰基或羧基）。还显示了1,2-二氢-4-R.sub.2 -5-[R.sub.3 CH(Br)CO]-6-R.sub.1 -2-氧代-3-吡啶基腈(II)作为中间体，以及制备I和II的方法。
• 5-Alkyl-1,6-naphthyridin-2(1H)-ones and cardiotonic use thereof
  申请人：Sterling Drug Inc.

  公开号：US04517190A1

  公开（公告）日：1985-05-14

  1-R"-3-Q-4-R'-5-R-1,6-naphthyridin-2(1H)-ones (I) or salts thereof, where R is lower-alkyl, R' is hydrogen or methyl, R" is hydrogen or lower-alkyl, and Q is hydrogen, hydroxy, amino, cyano, carbamyl, carboxy or aminocarbamyl, are useful as cardiotonic agents (I, Q is hydrogen, hydroxy, amino, cyano or carbamyl) and/or intermediates therefor (I, Q is carboxy, aminocarbamyl, hydrogen, amino, cyano or carbamyl). Also shown are 3-Q'-4-R'-5-(RCO)-6-[2-(di-lower-alkylamino)ethenyl]-2(1H)-pyridinones (II) or salts thereof, where R and R' are as above and Q' is hydrogen or cyano, which are useful as cardiotonics (II, Q' is hydrogen) and/or intermediates (II, Q' is cyano or hydrogen). Processes for preparing the compounds of formulas I and II are shown.

  1-R"-3-Q-4-R'-5-R-1,6-萘啶并[2(1H)-酮]（I）或其盐，其中R为低碳基，R'为氢或甲基，R"为氢或低碳基，Q为氢、羟基、氨基、氰基、氨基甲酰基、羧基或氨基甲酰基，作为强心剂（I，Q为氢、羟基、氨基、氰基或氨基甲酰基）和/或其中间体（I，Q为羧基、氨基甲酰基、氢、氨基、氰基或氨基甲酰基）有用。还显示了3-Q'-4-R'-5-(RCO)-6-[2-(二低碳基氨基)乙烯基]-2(1H)-吡啶酮（II）或其盐，其中R和R'如上所述，Q'为氢或氰基，它们作为强心剂（II，Q'为氢）和/或中间体（II，Q'为氰基或氢）有用。显示了制备公式I和II化合物的过程。
• 5-Alkanoyl-6-alkyl-2(1H)-pyridinones, their preparation and their
  申请人：Sterling Drug Inc.

  公开号：US04524149A1

  公开（公告）日：1985-06-18

  4-R.sub.2 -5-(Lower-alkanoyl)-6-(lower-alkyl)-2(1H)-pyridinones (I), useful as cardiotonics, where R.sub.2 is hydrogen or methyl, are prepared by reacting 2-(lower-alkanoyl)-1-(lower-alkyl)ethenamine (II) with lower-alkyl 2-propynoate or 2-butynoate respectively or by hydrolyzing 4-R.sub.2 -5-(lower-alkanoyl)-6-(lower-alkyl)-1,2-dihydro-2-oxonicotinonitrile (III), Q is CN) or corresponding 4-R.sub.2 -5-(lower-alkanoyl)-6-(lower-alkyl)-1,2-dihydro-2-oxonicotinamide to produce the corresponding 5-(lower-alkanoyl)-6-(lower-alkyl)-1,2-dihydro-2-oxonicotinic acid and decarboxylating said substituted nictotinic acid to produce I. Also disclosed and claimed are cardiotonic uses of 3-Q-4-R.sub.2 -5-(lower-alkanoyl)-6-(lower-alkyl)-2(1H)-pyridinones where Q is hydrogen or cyano and R.sub.2 is hydrogen or methyl (III). Also shown and claimed is methyl 4-acetyl-5-amino-2,4-hexadienoate or acid-addition salt thereof, useful as intermediate or cardiotonic.

  4-R.sub.2 -5-(低碳酰基)-6-(低烷基)-2(1H)-吡啶酮(I)是一种有益于心脏的强心剂，其中R.sub.2为氢或甲基，通过将2-(低碳酰基)-1-(低烷基)乙烯胺(II)分别与低烷基2-丙炔酸酯或2-丁炔酸酯反应或通过水解4-R.sub.2-5-(低碳酰基)-6-(低烷基)-1,2-二氢-2-氧基烟酰腈(III)(其中Q为CN)或相应的4-R.sub.2-5-(低碳酰基)-6-(低烷基)-1,2-二氢-2-氧基烟酰胺以产生相应的5-(低碳酰基)-6-(低烷基)-1,2-二氢-2-氧基烟酸，并脱羧化所述取代烟酸酸以产生I。还揭示和声明了3-Q-4-R.sub.2-5-(低碳酰基)-6-(低烷基)-2(1H)-吡啶酮的强心剂用途，其中Q为氢或氰，R.sub.2为氢或甲基(III)。还显示和声明了甲基4-乙酰基-5-氨基-2,4-己二烯酸酯或其酸盐加成物，可用作中间体或强心剂。
• Alkanoylpyridinones useful as cardiotonics and preparation thereof
  申请人：STERLING DRUG INC.

  公开号：EP0089022A2

  公开（公告）日：1983-09-21

  3-Q-4-R2-5-(Lower-alkanoyl)-6-(lower-alkyt)-2(1H)-pyridinones (I), useful as cardiotonics, where Q is hydrogen or cyano, R2 is hydrogen or methyl, are prepared by reacting 2-(lower-alkanoyl)-1-(lower-alkyl)ethenamine (II) with lower-alkyl 2-propynoate or 2-butynoate respectively or by hydrolyzing 4-R2-5-(lower-alkanoyl)-6-(lower-alkyl)-1,2-dihydro-2- oxonicotinonitrile or corresponding 4-R2-5-(lower-alkanoyl)-6-(lower-alkyl)-1,2-dihydro-2-oxonicotinamide to produce the corresponding 5-(lower-alkanoyl)-6-(lower-alkyl)-1,2-dihydro-2-oxonicotonic acid and decarboxylating said substituted nicotinic acid to produce I. Also shown and claimed is methyl 4-acetyl-5-amino-2,4-hexadienoate or acid-addition salt thereof, useful as intermediate or cardiontonic.

  3-Q-4-R2-5-(低级烷酰基)-6-(低级烷基)-2(1H)-吡啶酮 (I)，可用作强心剂，其中 Q 为氢或氰基，R2 为氢或甲基、分别通过 2-(低级烷酰基)-1-(低级烷基)乙烯胺 (II) 与低级烷基 2-丙炔酸酯或 2-丁炔酸酯反应，或通过水解 4-R2-5-(低级烷酰基)-6-(低级烷基)-1、或相应的 4-R2-5-(低级烷酰基)-6-(低级烷基)-1,2-二氢-2-氧代烟酰胺水解生成相应的 5-(低级烷酰基)-6-(低级烷基)-1,2-二氢-2-氧代烟酸，并将所述取代的烟酸脱羧生成 I。图中还显示并要求得到 4-乙酰基-5-氨基-2,4-己二烯酸甲酯或其酸加成盐，可用作中间体或心酮酸。
• 5-Alkyl-1,6-naphthyridin-2(1H)-ones, intermediates, their preparation and their cardiotonic use
  申请人：STERLING DRUG INC.

  公开号：EP0101952A1

  公开（公告）日：1984-03-07

  Naphthyridines of formula (I) , where R is -alkyl, R' is hydrogen or methyl, R" is hydrogen or alkyl, and Q is hydrogen, hydroxy, amino, cyano, carbamyl, carboxy or aminocarbamyl, are useful as cardiotonic agents (1, Q is hydrogen, hydroxy, amino, cyano or carbamyl) and/or intermediates therefor (I, Q is carboxy, aminocarbamyl, hydrogen, amino, cyano or carbamyl). Also shown are pyridinones of formula II where R and R' are as above and Q' is hydrogen or cyano, which are useful as cardiotonics (II, Q' is hydrogen) and/or intermediates (II, Q' is cyano or hydrogen). Processes for preparing the compounds of Formulas I and II are shown.

  式(I)的萘啶类化合物 其中 R 为烷基，R'为氢或甲基，R "为氢或烷基，Q 为氢、羟基、氨基、氰基、氨甲酰、羧基或氨基甲酰，可用作强心剂（1，Q 为氢、羟基、氨基、氰基或氨基甲酰）和/或其中间体（I，Q 为羧基、氨基甲酰、氢、氨基、氰基或氨基甲酰）。图中还显示了式 II 的吡啶酮类化合物 其中 R 和 R'如上，Q'为氢或氰基，可用作强心剂（II，Q'为氢）和/或中间体（II，Q'为氰基或氢）。所示为制备式 I 和 II 化合物的工艺。